Search Results

You are looking at 61 - 70 of 470 items for :

  • "paclitaxel" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Urmeel Patel, Nicole Hook, Meenakshi Malhotra, Perry Olshan, Paul R. Billings, Alexey Aleshin, and Angel Rodriguez

patient underwent neoadjuvant chemotherapy with dose dense AC (ddAC) followed by paclitaxel. Following one month, the patient underwent radical mastectomy, followed by adjuvant treatment and periodic radiological imaging, along with circulating tumor DNA

Full access

-agent tivozanib in patients with platinum-resistant ovarian cancer Contact: Nikki Neubauer, MD • 312-472-4684 Rachel Bers, BS • 312-472-5726 • r-bers@northwestern.edu ClinicalTrials.gov Identifier: NCT01853644 Phase I Trial of Intraperitoneal Nab-Paclitaxel

Full access

-639-5449 ClinicalTrials.gov Identifier: NCT01111825 Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity Principal Investigator: Mihaela Cristea, MD Condition

Full access

, Vanderbilt-Ingram Cancer Center • 800-811-8480 ClinicalTrials.gov Identifier: NCT00983268 A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer Principal Investigator

Full access

F. Anthony Greco

Med 2004 ; 350 : 2335 – 2342 . 4. Sandler AB Gray R Perry MC . Paclitaxel-carboplatin alone or with bevacizumab for non-small lung cancer . N Engl J Med 2006 ; 355 : 2542 – 2550 . 5. Moore MJ Goldstein D Hamm J . Erlotinib

Full access

Presented by: Nadeem R. Abu-Rustum

with external-beam RT, as well as interstitial brachytherapy, which is a sophisticated technology for the treatment of central pelvic recurrences. Use of modern chemotherapy regimens containing a combination of platinum and paclitaxel with drugs such

Full access

Leora Horn

in Oncology (NCCN Guidelines) for NSCLC, many chemotherapy drugs are useful for treating patients with advanced-stage NSCLC. Among them are platinum agents (eg, cisplatin, carboplatin), taxanes (eg, paclitaxel, albumin-bound paclitaxel, docetaxel

Full access

Athanassios Argiris

-fluoruracil (F) versus P, F and paclitaxel (T) as induction therapy in locally advanced head & neck cancer (LAHNC) (Abstr) . Proc Am Soc Clin Oncol 2003 ; 22 : A1997 . 8 Vermorken JB Remenar E Van Herpen C . Standard cisplatin/infusional 5

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain III, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

single agents in the metastatic disease setting based on several randomized phase III trials. 18 , 19 Cisplatin is a standard backbone of combination chemotherapy regimens, and cisplatin-based chemotherapy regimens (eg, cisplatin/paclitaxel

Full access

Maurie Markman

: 4265 – 4269 . 16 Francis P Rowinsky E Schneider J . Phase 1 feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study . J Clin Oncol 1995 ; 13 : 2961 – 2967 . 17 Markman